CD8+ T-cell response to NY-ESO-1: Relative antigenicity and in vitro immunogenicity of natural and analogue sequences

Clinical Cancer Research

Volumn 7, Issue 11 SUPPL., 2001, Pages

  Romero, Pedro ^a,c   Dutoit, Valerie ^a   Rubio Godoy, Verena ^a   Liénard, Danielle ^a   Speiser, Daniel ^a   Guillaume, Philippe ^a   Servis, Katerina ^b   Rimoldi, Donata ^b   Cerottini, Jean Charles ^a,b   Valmori, Danila ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Hopital Orthopedique de la Suisse Romande   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CTAG1B PROTEIN, HUMAN; GAMMA INTERFERON; HLA A2 ANTIGEN; MEMBRANE PROTEIN; PEPTIDE; PROTEIN; TUMOR ANTIGEN;

ARTICLE; BINDING COMPETITION; CD8+ T LYMPHOCYTE; CELL CULTURE; CELL SEPARATION; CHEMISTRY; DOSE RESPONSE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOLOGY; MELANOMA; METABOLISM; PROTEIN BINDING;

ANTIGENS; ANTIGENS, NEOPLASM; BINDING, COMPETITIVE; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; MELANOMA; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; PEPTIDES; PROTEIN BINDING; PROTEINS; TUMOR CELLS, CULTURED;

EID: 0035294118     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Van den Eynde, B. J., and van der Bruggen, P. T cell defined tumor antigens. Curr. Opin. Immunol., 9: 684-693, 1997.
2. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (Washington DC), 254: 1643-1647, 1991.
3. Sahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo. G., Schobert, I., and Pfreundschuh, M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA. 92: 11810-11813, 1995.
4. Marchand, M., van Baren, N., Weynants, P., Brichard, V., Dreno, B., Tessier, M. H., Rankin, E., Parmiani, G., Arienti, F., Humblet, Y., Bourlond, A., Vanwijck, R., Lienard, D., Beauduin, M., Dietrich, P. Y., Russo, V., Kerger, J., Masucci, G., Jager, E., De Greve, J., Atzpodien, J., Brasseur, F., Coulie, P. G., van der Bruggen, P., and Boon, T. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int. J. Cancer, 80: 219-230, 1999.
5. Chaux, P., Vantomme, V., Coulie, P., Boon, T., and van der Bruggen, P. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int. J. Cancer, 77: 538-542, 1998.
6. Valmori, D., Dutoit, V., Liénard, D., Rimoldi, D., Pittet, M., Champagne, P., Ellefsen, U., Sahin, U., Speiser, D., Lejeune, F., Cerottini, J-C., and Romero, P. Naturally occurring HLA-A2 restricted CD8+ T cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res., 60: 4499-4506, 2000.
7. Jager, E., Nagata, Y., Gnjatic, S., Wada, H., Stockert, E., Karbach, J., Dunbar, P. R., Lee, S. Y., Jungbluth, A., Jager, D., Arand, M., Ritter, G., Cerundolo, V., Dupont, B., Chen, Y. T., Old, L. J., and Knuth, A. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA, 97: 4760-4765, 2000.
8. Jager, E., Chen, Y. T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M., Wada, H., Noguchi, Y., Stockert, E., Old. L. J., and Knuth, A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med., 187: 265-720, 1998.
9. Valmori, D., Pittet, M. J., Vonarbourg, C., Rimoldi, D., Lienard, D., Speiser, D., Dunbar, R., Cerundolo, V., Cerottini, J. C., and Romero, P. Analysis of the cytolytic T lymphocyte response of melanoma patients to the naturally HLA-A*0201-associated tyrosinase peptide 368-376. Cancer Res., 59: 4050-4055, 1999.
10. Romero, P., Dunbar, P. R., Valmori, D., Pittet, M., Ogg, G. S., Rimoldi, D., Chen, J-L., Liénard, D., Cerottini, J. C., and Cerundolo, V. Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes. J. Exp. Med., 188: 1641-1650, 1998.
11. Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science (Washington DC), 274: 94-96, 1996.
12. Czerkinsky, C., Andersson, G., Ekre, H. P., Nilsson, L. A., Klareskog, L., and Ouchterlony, O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of γ-interferon-secreting cells. J. Immunol. Methods, 110: 29-36, 1988.
13. Valmori, D., Fonteneau, J. F., Lizana, C. M., Gervois, N., Lienard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J. C., and Romero, P. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J. Immunol., 160: 1750-1758, 1998.
14. Salcedo, M., Momburg, F., Hammerling, G. J., and Ljunggren, H. G. Resistance to natural killer cell lysis conferred by TAP1/2 genes in human antigen-processing mutant cells. J. Immunol., 152: 1702-1708, 1994.
15. Chen, Y. T., Scanlan, M. J., Sahin, U., Tureci, O., Gure, A. O., Tsang, S. L., Williamson, B., Stockert, E., Pfreundschuh, M., and Old, L. J. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA, 94: 1914-1918, 1997.
16. Wang, R. F., Johnston, S. L., Zeng, G., Topalian, S. L., Schwartzentruber, D. J., and Rosenberg, S. A. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol., 161: 3598-3606, 1998.
17. Stockert, E., Jager, E., Chen, Y. T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M., Knuth, A., and Old, L. J. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens [see comments]. J. Exp. Med., 187: 1349-1354, 1998.
18. Jager, E., Stockert, E., Zidianakis, Z., Chen, Y. T., Karbach, J., Jager, D., Arand, M., Ritter, G., Old, L. J., and Knuth, A. Humoral immune responses of cancer patients against "cancer-testis" antigen NY-ESO-1: correlation with clinical events. Int. J. Cancer, 84: 506-510, 1999.
19. Cox, A. L., Skipper, J., Chen, Y., Henderson, R. A., Darrow, T. L., Shabanowitz, J., Engelhard, V. H., Hunt, D. F., and Slingluff, C. L., Jr. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (Washington DC), 264: 716-719, 1994.
20. Valmori, D., Dutoit, V., Liénard, D., Lejeune, F., Speiser, D., Rimoldi, D., Cerundolo, V., Dietrich, P. Y., Cerottini, J-C., and Romero, P. Tetramer-guided analysis of TCR β-chain usage reveals a large repertoire of Melan-A-specific CD8+ T cells in melanoma patients. J. Immunol., 165: 533-538, 2000.
21. Valmori, D., Gervois, N., Rimoldi, D., Fonteneau, J. F., Bonelo, A., Lienard, D., Rivoltini, L., Jotereau, F., Cerottini, J. C., and Romero, P. Diversity of the fine specificity displayed by HLA-A*0201-restricted CTL specific for the immunodominant Melan-A/MART-1 antigenic peptide [published erratum appears in J. Immunol., 163: 1093, 1999]. J Immunol., 161: 6956-6962, 1998.
22. Romero, P., Pannetier, C., Herman, J., Jongeneel, C. V., Cerottini, J. C., and Coulie, P. G. Multiple specificities in the repertoire of a melanoma patient's cytolytic T lymphocytes directed against tumor antigen MAGE-1.A1. J. Exp. Med., 182: 1019-1028, 1995.
23. Sensi, M., and Parmiani, G. Analysis of TCR usage in human tumors: a new tool for assessing tumor-specific immune responses. Immunol. Today., 16: 588-595, 1995.